Key result
Multi-tyrosine kinase inhibitors show no increased risk of ischemic or cerebrovascular events versus matched non-cancer controls.
Why the study?
Cardiovascular toxicity of patients treated with small molecule tyrosine kinase inhibitors remains unclear despite common warnings of cardiovascular events in drug labels.
Do small molecule tyrosine kinase inhibitors increase the risk of ischemic heart disease, cerebrovascular accidents, and death in adults with advanced malignancy?
Cohort (n=130,057)
Do small molecule tyrosine kinase inhibitors increase the risk of ischemic heart disease, cerebrovascular accidents, and death in adults with advanced malignancy?
Answers are grounded in this paper and cite their sources.
In a real-world population of patients with advanced solid tumors, treatment with tyrosine kinase inhibitors did not increase the risk of ischemic heart disease or cerebrovascular accidents compared to matched controls without cancer.
BACKGROUND: Treatment with small molecule tyrosine kinase inhibitors (TKIs) has improved survival in many cancers, yet has been associated with an increased risk of adverse events. Warnings of cardiovascular events are common in drug labels of many TKIs. Despite these warnings, cardiovascular toxicity of patients treated with TKIs remains unclear. Here, we evaluate the cardiovascular outcomes of advanced cancer patients treated with small molecule tyrosine kinase inhibitors. METHODS: A population based cohort study was undertaken involving adults aged >18 years in Ontario, Canada, diagnosed with any advanced malignancy between 2006 and 2012. Data were extracted from linked administrative governmental databases. Adults with advanced cancer receiving TKIs were identified and followed throughout the time period. The main outcomes of interest were rates of hospitalization for ischemic heart disease (acute myocardial infarction and angina) or cerebrovascular accidents and death. RESULTS: 1642 patients with a mean age of 62.5 years were studied; 1046 were treated with erlotinib, 166 with sorafenib and 430 with sunitinib. Over the 380 day median follow-up period (range 6-1970 days), 1.1% of all patients had ischemic heart events, 0.7% had cerebrovascular accidents and 72.1% died. Rates of cardiovascular events were similar to age and gender-matched individuals without cancer. In a subgroup analysis of treatment patients with a prior history of ischemic heart disease, 3.3% had ischemic heart events while 1.2% had cerebrovascular accidents. CONCLUSIONS: TKIs do not appear to increase the cause-specific hazard of ischemic heart disease and cerebrovascular accidents compared to age and gender-matched individuals without advanced cancer.
No takes yet. Share an insight, caveat, or question.
Srikanthan et al. (2015) conducted a cohort in Advanced Solid Tumors (n=130,057). Multi-Tyrosine Kinase Inhibitors vs. Age and gender-matched individuals without cancer was evaluated on Ischemic heart events (acute myocardial infarction and angina) (HR 0.82, 95% CI 0.52-1.30, p=0.4). Multi-tyrosine kinase inhibitors did not increase the hazard of ischemic heart events or cerebrovascular accidents compared to matched individuals without cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: